Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
Clinical development of IL-18 therapies has been curtailed, however, by the protein’s lack of efficacy. We are currently selecting our lead IL-18 variant on the basis of potency for the IL-18 receptor, optimal pharmacokinetic profile and in vivo efficacy for inhibiting tumour growth. References: M; LWR.
98 
Let's personalize your content